Salute e Benessere

Clarivate Expands Real-World Data Offering with Addition of Social Determinant…

Crucial determinants such as income, education, ethnicity and smoking activity, coupled with unique predictive models around health conscientiousness and lifestyle habits, are known to significantly influence health outcomes and are captured within HealthWise Data's SDoH attributes. Through the partnership with HealthWise Data, these non-medical factors are integrated within the Clarivate Real-World Data Product, providing nuanced insights into patient populations, facilitating targeted…
PR Newswire
31/05/2024

SIFI receives positive CHMP opinion for AKANTIOR® (polihexanide 0.08%) in…

The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for AKANTIOR® in August 2024. The decision will then be applicable to all member states of the European Union as well as to Iceland, Liechtenstein and Norway. The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for AKANTIOR ®inAugust 2024. The decision will then be applicable to all...
PR Newswire
31/05/2024

Announcement of change in the total number of votes in AB SKF

AB SKF does not hold any own shares. AB SKF does not hold any own shares. Aktiebolaget SKF (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on31 May 2024at 08.00 CEST. For further information, please contact: Press Relations:Carl Bjernstam, +46 31-337 2517; +46 722 201 893;carl.bjernstam@skf.com Investor Relations:...
PR Newswire
31/05/2024

SciBase: Interim report

Important events during the quarter Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onMay 31, 2024. This year-end report has not been subject to review by the Company's auditors Contact person:Michael...
PR Newswire
31/05/2024

SciBase: Today is the first day of trading in the new shares and warrants of…

Number of shares and share capitalThrough the Capital Raising, the number of shares in SciBase has increased by 99,706,967 shares, from 119,831,437 shares to 219,538,404 shares. Through the Capital Raising, the share capital in the Company has increased by SEK 4,985,348.35, from SEK 5,991,571.85 to SEK 10,976,920.20. The Capital Raising has entailed a dilution of approximately 45 percent of the number of shares in the Company. Upon full exercise of the warrants of series TO 2, the Company's…
PR Newswire
31/05/2024

NX Europe Exhibits at LogiPharma 2024

Photo: NX Europe's boothhttps://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202405281403/_prw_PI1fl_nezZwWzb.jpg Photo: NX Europe's boothhttps://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202405281403/_prw_PI1fl_nezZwWzb.jpg LogiPharma is one ofEurope'slargest international pharmaceutical trade shows, focusing on issues, trends and the latest technologies in pharmaceutical and biopharmaceutical supply chains. The exhibition attracted approximately 2,000 participants from a...
PR Newswire
31/05/2024

Nyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase…

INSIDE INFORMATION REGULATED INFORMATIONNyxoah Announces Closing of Offering and Partial Exercise of Option to Purchase Additional SharesMont-Saint-Guibert, Belgium – May 31, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/ Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the closing of its previously announced...
Nasdaq GlobeNewswire
31/05/2024

Press Release: Dupixent recommended for EU approval by the CHMP to treat…

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU and the first new treatment approach for this disease in more than a decadeParis and Tarrytown, N.Y. May 31, 2024...
Nasdaq GlobeNewswire
31/05/2024

Press Release: Update on FDA priority review of Dupixent for the treatment of…

Update on FDA priority review of Dupixentfor the treatment of COPD patients with type 2 inflammationParis and Tarrytown, NY May 31, 2024. The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease (COPD). The revised target action...
Nasdaq GlobeNewswire
31/05/2024

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call…

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for...
Nasdaq GlobeNewswire
31/05/2024

dsm-firmenich implements a cross guarantee agreement to mitigate structural…

The cross-guarantee agreement will be made available on the company website, in the Investors/Debt & credit section. The cross-guarantee agreement will be made available on the company website, in the Investors/Debt & credit section. For more information, please contact: dsm-firmenich investor relations enquiries: Email:investors@dsm-firmenich.com dsm-firmenich media enquiries: Email:media@dsm-firmenich.com About dsm-firmenichAs innovators in nutrition,...
PR Newswire
31/05/2024

BioSenic S.A. : Information on the total number of voting rights and shares

PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, May 31, 2024, 7.00 am CEST –BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of...
Nasdaq GlobeNewswire
31/05/2024

Data from the PRECISION study of aprocitentan to be presented at the European…

Allschwil, Switzerland – May 31, 2024Idorsia Ltd (SIX: IDIA) today announced that data from the Phase 3 study of aprocitentan, Idorsia's endothelin receptor antagonist, will be presented by Prof. Krzysztof Narkiewicz, MD, PhD, at the European Society of Hypertension's 33 rd European Meeting of Hypertension and Cardiovascular Protection, taking place in Berlin, Germany, May 31 – June 3, 2024.An oral presentation is scheduled for Sunday, June 2 (09:05 – 09:15 CEST) in Convention Hall I...
Nasdaq GlobeNewswire
31/05/2024

FutureBridge set to engage with industry leaders at 2024 ASCO® Annual Meeting…

"At these conferences, we look forward to sharing our expertise on the future of medicines, healthcare solutions, disruptive trends, emerging technologies, and therapeutic platforms," said Shivali Jasrotia, Senior Consultant at FutureBridge. "We aim to strengthen relationships with existing clients and establish new collaborations with industry, academia, patient advocates, innovators, and key opinion leaders." "At these conferences, we look forward to sharing our…
PR Newswire
31/05/2024

One in Six Globally Concerned About Colorectal Cancer Screening Costs

CRC Screening Gaps Vary Globally: Nearly half (49.3%) of global respondents have never undergone CRC screening, with the highest proportions in Saudi Arabia (62.0%) and Poland (61.0%). CRC Screening Gaps Vary Globally : Nearly half (49.3%) of global respondents have never undergone CRC screening, with the highest proportions inSaudi Arabia(62.0%) andPoland(61.0%). Preference for Fecal Testing Over Colonoscopy : Although colonoscopies are more recognized (33.4%), fecal tests at...
PR Newswire
31/05/2024

Less Than 38% of Saudis Had Colorectal Cancer Screening

CRC Screening Gaps Vary Globally: A significant 49.3% of global respondents never had a CRC screening test, Saudi Arabia (62.0%) with the highest proportion. In addition, 39.7% Saudis believe there's not enough information available to assess their own CRC risk. CRC Screening Gaps Vary Globally : A significant 49.3% of global respondents never had a CRC screening test,Saudi Arabia(62.0%) with the highest proportion. In addition, 39.7% Saudis believe there's not enough information available...
PR Newswire
31/05/2024

Telix Announces Positive rPFS Data from ProstACT SELECT Trial of TLX591 rADC…

Nat Lenzo, MD, Nuclear Oncologist and General Internal Medicine Physician and lead recruiter onto the SELECT trial, commented, "We are encouraged by this rPFS result, which compares favourably to small molecule radioligand therapy (RLT) Phase I and II studies at similar stages of development[6]. This is a compelling signal of the potential efficacy of TLX591 in this heavily pre-treated population. The results further support the development of this candidate in an earlier mCRPC patient…
PR Newswire
31/05/2024

Novartis Phase III data confirm sustained efficacy and long-term safety of oral…

Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52) 1 Remibrutinib, an oral Bruton's tyrosine kinase inhibitor, demonstrated a favorable and consistent safety profile up to 1 year, including balanced liver function tests versus placebo 1 Novartis intends to submit remibrutinib for approval in chronic spontaneous urticaria (CSU) to global health authorities starting...
Nasdaq GlobeNewswire
31/05/2024

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First…

SOD1 -ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe 1QALSODY is Biogen's third rare disease therapy to be approved in the EU, demonstrating the company's commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the fieldCAMBRIDGE, Mass...
Nasdaq GlobeNewswire
30/05/2024

Pharming Group provides update on ongoing regulatory review of leniolisib for…

Leiden , the Netherlands, May 30, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Authorisation Application (MAA) for leniolisib for the treatment of adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta syndrome (APDS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Nasdaq GlobeNewswire
30/05/2024

Endo Provides Select First-Quarter 2024 Financial Results for Endo International…

EIPFIRST-QUARTER FINANCIAL PERFORMANCE(in thousands) EIPFIRST-QUARTER FINANCIAL PERFORMANCE (in thousands) EIP CONSOLIDATED FINANCIAL RESULTSTotal revenues were$420 millionin first-quarter 2024, a decrease of 19% compared to$515 millionin first-quarter 2023. This decrease was primarily attributable to decreased revenues from the Generic Pharmaceuticals segment. Reported Net Loss in first-quarter 2024 was$154 millioncompared to reported Net Loss of$3 millionin...
PR Newswire
30/05/2024

DBV Technologies to Participate in Upcoming EAACI 2024 Congress

DBV Technologies to Participate in Upcoming EAACI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced its upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress May 31 – June 3 in Valencia, Spain. A flash talk presentation...
Nasdaq GlobeNewswire
30/05/2024

Galapagos and Adaptimmune sign clinical collaboration agreement with an option…

Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initialin vitrotesting...
Nasdaq GlobeNewswire
30/05/2024

Calliditas partner STADA receives positive CHMP opinion recommending full…

"This is an important day for patients suffering from IgAN in Europe as Kinpeygo represents the first ever fully approved medication for this rare kidney disease. The long-term confirmatory trial met its eGFR endpoint with high statistical significance and we are delighted that EMA now has issued a positive opinion," said Renee Aguiar-Lucander, CEO. "This is an important day for patients suffering from IgAN inEuropeas Kinpeygo represents the first ever fully approved medication…
PR Newswire
30/05/2024
Altri  Comunicati